CN112778572A - Collagen-based material capable of inhibiting new blood vessels and preparation method thereof - Google Patents
Collagen-based material capable of inhibiting new blood vessels and preparation method thereof Download PDFInfo
- Publication number
- CN112778572A CN112778572A CN202110002779.0A CN202110002779A CN112778572A CN 112778572 A CN112778572 A CN 112778572A CN 202110002779 A CN202110002779 A CN 202110002779A CN 112778572 A CN112778572 A CN 112778572A
- Authority
- CN
- China
- Prior art keywords
- collagen
- solution
- graphene oxide
- serum albumin
- bovine serum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001436 collagen Polymers 0.000 title claims abstract description 66
- 102000008186 Collagen Human genes 0.000 title claims abstract description 65
- 108010035532 Collagen Proteins 0.000 title claims abstract description 65
- 239000000463 material Substances 0.000 title claims abstract description 29
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 21
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 210000004204 blood vessel Anatomy 0.000 title claims description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract description 30
- 229940098773 bovine serum albumin Drugs 0.000 claims abstract description 29
- 229910021389 graphene Inorganic materials 0.000 claims abstract description 29
- 238000007710 freezing Methods 0.000 claims abstract description 19
- 230000008014 freezing Effects 0.000 claims abstract description 19
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims abstract description 15
- 206010029113 Neovascularisation Diseases 0.000 claims abstract description 12
- 150000001718 carbodiimides Chemical class 0.000 claims abstract description 11
- 239000000515 collagen sponge Substances 0.000 claims abstract description 6
- 238000001816 cooling Methods 0.000 claims abstract description 6
- 238000005266 casting Methods 0.000 claims abstract description 5
- 238000006243 chemical reaction Methods 0.000 claims abstract description 5
- 238000004132 cross linking Methods 0.000 claims abstract description 5
- 238000002791 soaking Methods 0.000 claims abstract description 5
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 claims abstract description 3
- 238000010521 absorption reaction Methods 0.000 claims abstract description 3
- 239000000512 collagen gel Substances 0.000 claims abstract description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 238000009777 vacuum freeze-drying Methods 0.000 claims description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- 238000009740 moulding (composite fabrication) Methods 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 7
- 206010027476 Metastases Diseases 0.000 abstract description 6
- 230000009401 metastasis Effects 0.000 abstract description 6
- 238000002054 transplantation Methods 0.000 abstract description 4
- 230000012010 growth Effects 0.000 abstract description 3
- 239000000126 substance Substances 0.000 abstract description 3
- 238000004108 freeze drying Methods 0.000 abstract description 2
- 239000012567 medical material Substances 0.000 abstract description 2
- 238000000465 moulding Methods 0.000 abstract description 2
- 210000001519 tissue Anatomy 0.000 description 7
- 239000012528 membrane Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 239000003431 cross linking reagent Substances 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 238000007306 functionalization reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J9/00—Working-up of macromolecular substances to porous or cellular articles or materials; After-treatment thereof
- C08J9/36—After-treatment
- C08J9/40—Impregnation
- C08J9/42—Impregnation with macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
- A61L27/44—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
- A61L27/446—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with other specific inorganic fillers other than those covered by A61L27/443 or A61L27/46
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/56—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/58—Materials at least partially resorbable by the body
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J3/00—Processes of treating or compounding macromolecular substances
- C08J3/24—Crosslinking, e.g. vulcanising, of macromolecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/602—Type of release, e.g. controlled, sustained, slow
- A61L2300/604—Biodegradation
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2389/00—Characterised by the use of proteins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2489/00—Characterised by the use of proteins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K3/00—Use of inorganic substances as compounding ingredients
- C08K3/02—Elements
- C08K3/04—Carbon
- C08K3/042—Graphene or derivatives, e.g. graphene oxides
Abstract
A collagen-based material capable of inhibiting new vessels and a preparation method thereof, belonging to the field of medical materials. Firstly, preparing a collagen solution, adding carbodiimide and N-hydroxysuccinimide solution into the collagen solution to perform a crosslinking reaction, and casting the crosslinked collagen solution into a mould; cooling the collagen gel in a gradient manner and freezing to obtain a collagen sponge scaffold; adding the graphene oxide solution into a bovine serum albumin solution to prepare a graphene oxide-bovine serum albumin solution; and soaking the crosslinked collagen scaffold into a graphene oxide-bovine serum albumin solution for sufficient absorption, performing gradient cooling again, freezing, and performing freeze drying molding to obtain the collagen-based material capable of inhibiting the neovascularization. The material has simple preparation process, controllable forming and simple equipment. The material has good physical and chemical properties and biocompatibility, and can be used for clinically inhibiting the growth and metastasis of tumor parts or the neovascularization phenomenon after corneal transplantation and other conditions.
Description
Technical Field
The invention belongs to the field of medical materials, relates to a collagen-based material capable of inhibiting new vessels and a preparation method thereof, and particularly relates to a method for preparing a collagen-based material capable of inhibiting new vessels, which has good physicochemical property and biocompatibility. The material obtained by the invention can be applied to inhibiting the growth and metastasis of tumor parts clinically, or the phenomenon of neovascularization under various conditions after corneal transplantation and the like.
Background
Vascular tissue is the most important factor affecting tumor growth and metastasis. Tumor cells can initiate neovascularization by secreting specific factors such as vascular endothelial growth factor. The new blood vessels can provide nutrition and oxygen support for the growth of tumor cells, and provide special channels for the metastasis of tumors (liver, lung, bone, brain, and the like) in organs, thereby further worsening the tumors. At present, common methods such as surgery, chemotherapy and the like can only treat tumor cells, but neglects to inhibit tumor blood vessels, so that roots are left for relapse and metastasis of tumors, and the problems to be solved by current clinical treatment are solved. In addition, in the case of corneal transplantation or the like, the vision recovery of the patient is also affected by the new vascular tissue. Therefore, effective inhibition of new blood vessels is important for clinically inhibiting growth and metastasis of tumor sites, or angiogenesis occurring in corneal transplantation, and the like.
Collagen (Collagen) plays a role of binding tissues in animal cells as the most important insoluble fibrin outside human tissue cells, and is a skeleton constituting an extracellular matrix in which Collagen forms semicrystalline fibers, providing tension and elasticity to cells, and plays a role in migration and development of cells. The collagen has good biocompatibility, good physical and chemical properties, easy processability and degradability. Therefore, the collagen-based material is an ideal biomedical polymer material and has wide application prospect in the field of various tissue organ repair. Currently, graphene oxide attracts a wide attention in the field of nano biomedicine due to its advantages of good water solubility and stability, huge specific surface area, abundant oxygen-containing functional groups, easy modification and functionalization, and the like. Researches show that the graphene oxide is an excellent carrier of hydrophobic drugs, peptides, proteins, nucleic acids and the like, and has attractive application prospects in the aspects of efficient targeted transportation of drugs, biological analysis and sensing, composite nano biological materials and the like.
According to the research, a bovine serum albumin modified graphene oxide component is introduced into the collagen-based scaffold material, so that the collagen-based material which has good physical and chemical properties and biocompatibility and can inhibit new vessels is obtained. The collagen-based material capable of inhibiting the neovascularization obtained by the patent has wide market prospect.
Disclosure of Invention
The invention aims to overcome the defects of the prior art and provide a collagen-based material capable of inhibiting new vessels and a preparation method thereof.
The purpose of the invention is realized by the following technical scheme:
a preparation method of collagen-based material capable of inhibiting new blood vessels comprises the following steps:
(1) preparing a collagen solution with a certain concentration, adding carbodiimide and N-hydroxysuccinyl into the collagen solution according to a certain proportion, fully stirring to carry out a crosslinking reaction, and casting the crosslinked collagen solution into a mould;
(2) pre-freezing the collagen gel obtained in the step (1) at-20 ℃, then pre-freezing at-80 ℃, and then carrying out vacuum freeze drying for more than 48 hours to obtain a collagen sponge scaffold with a uniform structure;
(3) respectively preparing a graphene oxide solution and a bovine serum albumin solution with certain concentrations;
(4) adding the graphene oxide solution obtained in the step (3) into a bovine serum albumin solution to prepare a graphene oxide-bovine serum albumin solution with a certain concentration;
(5) and (3) soaking the collagen sponge scaffold obtained in the step (2) into the graphene oxide-bovine serum albumin solution obtained in the step (4) for sufficient absorption, then performing gradient cooling again, freezing, and performing freeze drying and molding to obtain the collagen-based material capable of inhibiting the neovascularization.
Further, in the step (1), the collagen raw material is sourced from cowhells, and 0.01-0.1 mol/L acetic acid or hydrochloric acid solution is used for preparing a collagen solution; the concentration of collagen in the collagen solution in the step (1) is 5-8 mg/mL, and the mass ratio of carbodiimide to collagen in the collagen solution is 1: (5.5-6.5), wherein the mass ratio of the carbodiimide to the N-hydroxysuccinimide is 1: (0.6 to 1.2)
Further, in the step (2), the pre-freezing time at the temperature of-20 ℃ is 12-24 hours, and the pre-freezing time at the temperature of-80 ℃ is more than 24 hours; the temperature for vacuum freeze-drying was-50 ℃.
Further, in the step (3), the concentration of the graphene oxide solution is 0.05-0.15 mug/mL, and the concentration of the bovine serum albumin solution is 10-200 mug/mL.
Further, the concentration of the graphene oxide-bovine serum albumin solution in the step (4) is 30-180 [ mu ] g/mL.
Further, in the step (5), the mass ratio of the graphene oxide-bovine serum albumin to the collagen-based sponge scaffold material obtained in the step (2) is 0.5-3.5%.
The graphene oxide-collagen-based composite material loaded with bovine serum albumin obtained by the invention has the possibility of inhibiting the neovascularization phenomenon generated at tissue defect parts such as cornea, cartilage and the like clinically, thereby promoting the normal repair of tissues.
Detailed Description
The invention will be further described with reference to the following examples for a better understanding of the invention, but the scope of the invention as claimed is not limited to the scope represented by the examples mentioned.
Example 1
Collagen, graphene oxide and bovine serum albumin are used as raw materials to prepare the collagen-based scaffold material capable of inhibiting the neovascularization. The preparation steps of the functionalized collagen-based material are as follows:
(1) preparing a collagen solution with the concentration of 6mg/mL, adding carbodiimide (EDC) and N-hydroxysuccinyl (NHS) into the collagen solution according to a certain proportion as a cross-linking agent and a catalyst, and controlling the collagen: EDC: NHS 6:1:1, fully stirring to generate a crosslinking reaction, and casting the crosslinked collagen solution into a mould for gelling;
(2) absorbing water for more than 2 hours to reach saturation of the collagen membrane obtained in the step (1), then transferring to 0 ℃ for freezing for 2 hours, pre-freezing for 24 hours at-20 ℃, pre-freezing for 48 hours at-80 ℃, and then freezing and drying for more than 48 hours at-50 ℃ in vacuum to obtain a cross-linked collagen sponge scaffold with a uniform structure;
(3) respectively preparing a graphene oxide solution with the concentration of 0.1 mug/mL and a bovine serum albumin solution with the concentration of 180 mug/mL;
(4) adding the graphene oxide solution obtained in the step (3) into a bovine serum albumin solution to prepare a graphene oxide-bovine serum albumin solution with the concentration of 150 mug/mL;
(5) and (3) soaking the crosslinked collagen scaffold obtained in the step (2) into the oxidized graphene-bovine serum albumin solution obtained in the step (4) to fully absorb for 24 hours, then performing gradient cooling again according to the sequence of the step (2), freezing, drying and forming to obtain the novel collagen-based scaffold material capable of inhibiting neovascularization.
Example 2
Collagen, graphene oxide and bovine serum albumin are used as raw materials to prepare the collagen-based membrane material capable of inhibiting the neovascularization. The preparation steps of the functionalized collagen-based material are as follows:
(1) preparing a collagen solution with the concentration of 5.5mg/mL, adding carbodiimide (EDC) and N-hydroxysuccinyl (NHS) into the collagen solution according to a certain proportion as a cross-linking agent and a catalyst, and controlling the collagen: EDC: NHS 6:1:1, fully stirring to generate a crosslinking reaction, casting the crosslinked collagen solution into a culture dish, and naturally drying to form a film;
(2) absorbing water for more than 2 hours to reach saturation of the collagen membrane obtained in the step (1), then transferring to 0 ℃ for freezing for 2 hours, pre-freezing for 12 hours at-20 ℃, then pre-freezing for 48 hours at-80 ℃, and then carrying out vacuum freeze drying at-50 ℃ for more than 48 hours to obtain the collagen-based material with the micro-rough surface structure;
(3) respectively preparing a graphene oxide solution with the concentration of 0.15 mug/mL and a bovine serum albumin solution with the concentration of 150 mug/mL;
(4) adding the graphene oxide solution obtained in the step (3) into a bovine serum albumin solution to prepare a graphene oxide-bovine serum albumin solution with the concentration of 150 mug/mL;
(5) and (3) soaking the collagen-based material obtained in the step (2) into the graphene oxide-bovine serum albumin solution obtained in the step (4) for fully adsorbing for 24 hours, then performing gradient cooling again according to the sequence of the step (2), freezing, drying and forming to obtain the new collagen-based membrane material capable of inhibiting new vessels.
Claims (7)
1. A preparation method of a collagen-based material capable of inhibiting new blood vessels is characterized by comprising the following steps:
(1) preparing a collagen solution with a certain concentration, adding carbodiimide and N-hydroxysuccinyl into the collagen solution according to a certain proportion, fully stirring to carry out a crosslinking reaction, and casting the crosslinked collagen solution into a mould;
(2) pre-freezing the collagen gel obtained in the step (1) at-20 ℃, then pre-freezing at-80 ℃, and then carrying out vacuum freeze drying for more than 48 hours to obtain a collagen sponge scaffold with a uniform structure;
(3) respectively preparing a graphene oxide solution and a bovine serum albumin solution with certain concentrations;
(4) adding the graphene oxide solution obtained in the step (3) into a bovine serum albumin solution to prepare a graphene oxide-bovine serum albumin solution with a certain concentration;
(5) and (3) soaking the collagen sponge scaffold obtained in the step (2) into the graphene oxide-bovine serum albumin solution obtained in the step (4) for sufficient absorption, then performing gradient cooling again according to the sequence of the step (2), freezing, drying and forming to obtain the collagen-based material capable of inhibiting neovascularization.
2. The preparation method according to claim 1, wherein the collagen raw material in the step (1) is derived from cowhells, and the collagen solution is prepared by using 0.01-0.1 mol/L acetic acid or hydrochloric acid solution; the concentration of collagen in the collagen solution in the step (1) is 5-8 mg/mL, and the mass ratio of carbodiimide to collagen in the collagen solution is 1: (5.5-6.5), wherein the mass ratio of the carbodiimide to the N-hydroxysuccinimide is 1: (0.6-1.2).
3. The method according to claim 1, wherein the prefreezing time at-20 ℃ in the step (2) is 12 to 24 hours, and the prefreezing time at-80 ℃ is 24 hours or more; the temperature for vacuum freeze-drying was-50 ℃.
4. The method according to claim 1, wherein the graphene oxide solution in step (3) has a concentration of 0.05 to 0.15 μ g/mL, and the bovine serum albumin solution has a concentration of 10 to 200 μ g/mL.
5. The method according to claim 1, wherein the concentration of the graphene oxide-bovine serum albumin solution in the step (4) is 30-180 μ g/mL.
6. The preparation method according to claim 1, wherein the graphene oxide-bovine serum albumin in the step (5) accounts for 0.5-3.5% of the collagen-based sponge scaffold material obtained in the step (2) by mass.
7. A collagen-based material capable of inhibiting neovascularization, which is produced by the production method according to any one of claims 1 to 6.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110002779.0A CN112778572A (en) | 2021-01-04 | 2021-01-04 | Collagen-based material capable of inhibiting new blood vessels and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110002779.0A CN112778572A (en) | 2021-01-04 | 2021-01-04 | Collagen-based material capable of inhibiting new blood vessels and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112778572A true CN112778572A (en) | 2021-05-11 |
Family
ID=75753802
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110002779.0A Pending CN112778572A (en) | 2021-01-04 | 2021-01-04 | Collagen-based material capable of inhibiting new blood vessels and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112778572A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105037787A (en) * | 2015-07-21 | 2015-11-11 | 常州大学 | Taurine modified collagen base material and preparing method thereof |
| CN111135344A (en) * | 2020-02-27 | 2020-05-12 | 福州大学 | Scaffold for repairing carbon nano tube/collagen-based cartilage of composite albumin and preparation method thereof |
-
2021
- 2021-01-04 CN CN202110002779.0A patent/CN112778572A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105037787A (en) * | 2015-07-21 | 2015-11-11 | 常州大学 | Taurine modified collagen base material and preparing method thereof |
| CN111135344A (en) * | 2020-02-27 | 2020-05-12 | 福州大学 | Scaffold for repairing carbon nano tube/collagen-based cartilage of composite albumin and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4214051B2 (en) | Elastin crosslinked body and method for producing the same | |
| EP2370115B1 (en) | Hydrogel sponges, methods of producing them and uses thereof | |
| EP2150282B1 (en) | Compositions and methods for scaffold formation | |
| Jabbari et al. | The matrix reloaded: the evolution of regenerative hydrogels | |
| Fang et al. | A biocompatible vascularized graphene oxide (GO)-collagen chamber with osteoinductive and anti-fibrosis effects promotes bone regeneration in vivo | |
| CN114601958A (en) | Hyaluronic acid/silk fibroin double-crosslinking injectable hydrogel and preparation method thereof | |
| Dai et al. | Improved thermostability and cytocompatibility of bacterial cellulose/collagen composite by collagen fibrillogenesis | |
| Zhang et al. | Advances in photocrosslinkable materials for 3D bioprinting | |
| Yao et al. | Facile incorporation of REDV into porous silk fibroin scaffolds for enhancing vascularization of thick tissues | |
| JP5990298B2 (en) | Cell structure for cell transplantation and cell assembly for cell transplantation | |
| Jin et al. | Multifunctional biomimetic hydrogel based on graphene nanoparticles and sodium alginate for peripheral nerve injury therapy | |
| CN113583455B (en) | Collagen-modified chitosan double-network hydrogel, biological ink, preparation method and application | |
| CN107519535B (en) | Degradable sodium alginate/fibroin double-layer skin tissue engineering scaffold material and preparation method thereof | |
| Chen et al. | Polydopamine modified acellular dermal matrix sponge scaffold loaded with a-FGF: Promoting wound healing of autologous skin grafts | |
| CN111588911B (en) | Composite material for slowly releasing exosome and preparation method and application thereof | |
| WO2015190430A1 (en) | Cell structure and method for producing cell structure | |
| Zhao et al. | Hydroxypropyl chitosan/soy protein isolate conduits promote peripheral nerve regeneration | |
| CN112778572A (en) | Collagen-based material capable of inhibiting new blood vessels and preparation method thereof | |
| KR20060091350A (en) | Polymer scaffold for tissue engineering using collagen extracted from marine life and extraction method thereof | |
| CN113604421B (en) | Vascularized double-layer engineering skin based on 3D printing and preparation method thereof | |
| CN113999410B (en) | Preparation method of double-crosslinked antibacterial hydrogel for repairing burn and scald wound | |
| JPWO2003094985A1 (en) | Artificial extracellular matrix and method for producing the same | |
| WO2011082565A1 (en) | Artificial nerve graft with neurotrophic factor fixed by genipin and preparation method thereof | |
| CN113730657A (en) | collagen-PEG self-assembly slow release system and preparation method and application thereof | |
| WO2009122710A1 (en) | Medical composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210511 |